Trials / Withdrawn
WithdrawnNCT05918250
mRNA-2736 for Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
A Phase 1, Open-Label, Multicenter, Study of mRNA-2736 in Patients With Relapsed or Refractory Multiple Myeloma
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- ModernaTX, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to evaluate the safety and tolerability of mRNA-2736 in participants with RRMM.
Detailed description
This open-label, Phase 1, dose-escalation, first-in-human (FIH) clinical study of mRNA-2736 in participants with RRMM is designed to evaluate the safety and tolerability of escalating doses of mRNA-2736, administered intravenously (IV), to determine maximum tolerated dose and/or recommended Phase 2 dose, pharmacokinetics, pharmacodynamics, and preliminary efficacy of mRNA-2736.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | mRNA-2736 | mRNA-2736 will be administered IV. |
Timeline
- Start date
- 2023-08-15
- Primary completion
- 2026-05-27
- Completion
- 2026-05-27
- First posted
- 2023-06-26
- Last updated
- 2023-08-18
Locations
13 sites across 2 countries: United States, Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05918250. Inclusion in this directory is not an endorsement.